Quantification of tumor uptake of iodized oils and emulsions of iodized oils: Experimental study

Radiology

Volumn 201, Issue 3, 1996, Pages 731-735

  De Baere, Thierry ^a   Zhang, Xiaowei ^a   Aubert, Bernard ^a   Harry, Gerard ^a   Lagrange, Christine ^a   Ropers, Jacques ^a   Dufaux, Jacques ^b   Lumbroso, Jean ^a   Rougier, Philippe ^a   Ducreux, Michel ^a   Roche, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris 1   (France)

Author keywords

chemotherapeutic infusion; Contrast media, fatty acid; Hepatic arteries, therapeutic blockade; Liver neoplasms

Indexed keywords

IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 125; IODINE 131; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; EMULSION; FEMALE; HEPATIC ARTERY; LIVER TUMOR; LUNG; NONHUMAN; PHARMACEUTICS; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT; RADIATION DOSE; VISCOSITY;

EID: 10544252270     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.201.3.8939223     Document Type: Article

References (22)

1. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985; 154:15-17.
2. Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985; 154:19-24.
3. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 162:345-351.
4. Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984; 54:2367-2374.
5. Roche A. Chemoembolization of liver malignancies. In: Ferrucci JT, Mathieu D, eds. Advances in hepatobiliary radiology. St Louis, Mo: Mosby, 1990; 295-305.
6. Iwai K, Maeda H, Konno T. Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 1987; 7:321-328.
7. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
8. Bruneton JN, Kerboul P, Grimaldi C, et al. Hepatic intraarterial Lipiodol: technique, semiologic patterns, and value for hepatic tumors. Gastrointest Radiol 1988; 13:45-51.
9. Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol 1990; 63:771-775.
10. Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I-131-labeled Lipiodol: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168:541-545.
11. Yoo HS, Park CH, Lee JT, et al. Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 1994; 33(suppl):S128-S133.
12. de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology 1995; 194:165-170.
13. Park J, Jeon S, Kang H, Im J, Han M, Kim C. Transcatheter renal arterial embolization with the mixture of ethanol and iodized oil (Lipiodol). Invest Radiol 1986; 21:577-580.
14. Perring S, Hind R, Fleming J, Birch S, Batty V, Taylor I. Dosimetric assessment of radiolabeled Lipiodol as a potential therapeutic agent in colorectal liver metastases using combined CT and SPECT. Nucl Med Commun 1994; 15:34-38.
15. Lorcher U, Peters J, Kollath J. Veranderungen der lunge und pleura nach chemoemboliztion von lebertumoren mitmitomycin-Lipiodol. ROFO 1990; 152:569-573.
16. Cay O, Kruskal J, Thomas P, Clause ME. Targeting of different ethiodized oil-doxorubicin mixtures to hypervascular hepatic metastases with intraarterial and intraportal injections. JVIR 1996; 7:409-417.
17. Kawaguchi T, Fukushima S, Hayashi Y, Kaneko M, Nakano M. Selective accumulation of 3,5-dioc-tanoyl-5-fluoro-2-deoxyuridine (FdUrd-C8) and sustained release of its active metabolites in VX2 rabbit hepatoma following intraarterial administration of FdUrd-C8 solution in Lipiodol. Cancer Res 1988; 48:4179-4183.
18. Zhao Z, Ramirez LN, Simenauer N. Pharmacokinetics of intraarterial hepatic THP-Adriamycin-Lipiodol in rabbits with VX2 tumors. Regional Cancer Treat 1993; 4:213-217.
19. Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70:585-590.
20. Fukushima S, Kubota M, Kojima T, et al. Preparation and evaluation of two formulations: cisplatin suspension in Lipiodol and polylactic acid microspheres containing aclarubicin hydrochloride for hepatic arterial administration therapy for hepatocellular carcinoma. Regional Cancer Treat 1992; 2:36-39.
21. Van Beers B, Roche A, Cauquil P. Transcatheter arterial chemotherapy using doxorubicin, iodized oil, and Gelfoam embolization in hepatocellular carcinoma. Acta Radiol 1989; 30:415-418.
22. Imaeda T, Ymawaki Y, Seki M, et al. Lipiodol retention and massive necrosis after Lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 1993; 16:209-213.